



Review Article

Experimental evidence for use of *Acorus calamus* (asarone) for cancer chemopreventionBhriku Kumar Das^{a,b}, AHM Viswanatha Swamy^a, Basavaraj C. Koti^a, Pramod C. Gadad^{a,b,*}^a KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education and Research, Belagavi), Vidyanagar, Hubballi, 580 031, Karnataka, India^b Off-campus Basic and Applied Sciences Research Centre of KLE Academy of Higher Education and Research at KLE College of Pharmacy, Vidyanagar, Hubballi, 580 031, Karnataka, India

ARTICLE INFO

Keywords:

Evidence-based medicine
Oncology
Biochemistry
Cancer research
Cell biology
Molecular biology

ABSTRACT

Cancer is one of the major non-communicable diseases posing substantial challenges in both developing and developed countries. The options available for treatment of different cancer are associated with various limitations, including severe toxicity, drug resistance, poor outcomes and a high risk of relapse. Hence, an increased attention and necessity for screening of various phytochemicals from natural sources for superior and safer alternative has been ongoing for several decades. In recent years, phytochemicals like galantamine, erwinaze, rivastigmine, resveratrol from natural sources have been found to be important therapeutic targets for the treatment of various diseases including cancer, neurodegeneration, diabetes, and cardiovascular effects. *Acorus calamus* (Sweet flag), and/or its bioactive phytochemical alpha (α)-and beta (β)-asarone, is a well-known drug in the traditional system of medicine which possesses anti-tumor and chemo-preventive activities as evident from numerous pre-clinical studies both *in-vitro* and *in-vivo*. In this article, we critically review the current available scientific evidences of *A. calamus* and/or asarone for cancer chemoprevention based on preclinical *in-vitro* and *in-vivo* models. In addition, we also have compiled and discussed the molecular targets of mechanism(s) involved in the anti-cancer activity of *A. calamus*/asarone. Still, extensive *in-vivo* studies are necessary using various animal models to understand the molecular mechanism behind the pharmacological activity of the bioactive phytochemicals derived from *A. calamus*. It is strongly believed that the comprehensive evidence presented in this article could deliver a possible source for researchers to conduct future studies pertaining to *A. calamus* and/or its bioactive phytochemicals asarone for cancer chemoprevention.

1. Introduction

The cancer is a major non-communicable disease posing substantial social and economical challenges in both developing and developed countries. The rapid rise in cancer mortality rates accounting together for China, India and Russia is nearly twofold high compared to the UK and the USA. The number of factors contributed for rapid rise in cancer incidence in the growing economies include changes in lifestyles (food habit, decreased physical activity and sedentary lifestyles), low socio-income populations with minimum cancer care facility, different contaminants of the environment, increase in aged populations, and increase in oncogenic communicable infective organisms [1, 2]. According to International Agency for Research on Cancer GLOBOCAN project, the rise in the cancer burden in India will nearly be double in the next 20 years and is predicted to be more than 1.7 million cases by 2035 [2,3].

In the current scenario, the options available for treatment of different cancer are associated with various limitations, including severe toxicity, drug resistance, poor outcomes and a high risk of relapse. Hence, an increased attention and necessity for screening of various phytochemicals from natural sources for superior and safer alternative has been ongoing for several decades. The chemo-preventive agents available from the different parts of plants are used in the form of alternative and evidence-based complementary system of medicine along with the current chemotherapy and/or radiation therapy [4]. The recent research focus has shifted to the molecular mechanisms of these natural phytoconstituents on various signal transduction mechanisms controlling the cell growth and the cell cycle.

Acorus calamus (L.) (Sweet flag), a member of the family Acoraceae, generally used alone or in combination with other herbs in Indian and Chinese traditional medicine has generated great interest and is found to

* Corresponding author.

E-mail address: gadadpramod@gmail.com (P.C. Gadad).<https://doi.org/10.1016/j.heliyon.2019.e01585>

Received 13 November 2018; Received in revised form 20 April 2019; Accepted 24 April 2019

2405-8440/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

be beneficial [5]. *Acorus gramineus* (S.) and *Acorus tatarinowii* (S.) (Acoraceae), the other plants from *Acorus* species are officially listed in the Chinese Pharmacopoeia [6, 7]. The plant is widely cultivated in different parts of temperate and sub-temperate regions of the world and is native to India, Sri Lanka, Japan, China, Burma, Mongolia, Southern Russia, Europe and Northern USA [8, 9]. The habitat of the herbaceous perennial plant *A. calamus*, is semi-aquatic and terrestrial with creeping rhizomes. The rhizomes are bitter in taste, highly branched, pinkish or pale green in color and citrus in odor [8, 10]. In this review, we have summarized and discussed the anti-cancer properties of *A. calamus* and/or its main bioactive phytochemicals asarone (alpha (α)- and beta (β)-asarone) and related mechanisms based on *in-vitro* and *in-vivo* experimental evidences.

1.1. Chemical constituents of *Acorus calamus*

In general, *A. calamus* consists of various phytoconstituents namely glycosides (xanthone), volatile oil, sesquiterpenes, monoterpenes, flavonoids, steroids, saponins, lignin, tannins, mucilage, alkaloid and polyphenolic compounds [11, 12]. The two main bioactive aromatic constituents isolated from the rhizomes of *A. calamus* are alpha (α)-asarone (1,2,4-trimethoxy-5-[(E)-prop-1-enyl] benzene) and beta (β)-asarone (1, 2, 4-trimethoxy-5-[(Z)-prop-1-enyl] benzene). Beside these, it also contains the other essential oil such as calamenol, calameon and calamen. The chemical structures of the various constituents of *A. calamus* are illustrated in Fig. 1 [5,13,14].

1.2. Ethnomedicinal and pharmacological properties of *Acorus calamus*

The traditional use of *Acorus calamus* in Indian Ayurvedic system is widely accepted. The plant has been used to cure several diseases like asthma, fever, cough, epilepsy, hysteria, skin diseases, depression, haemorrhoids, diarrhea, insomnia, dysentery, kidney and liver problems, mental retardation, bronchitis and as a sedative. The external application of the paste of *A. calamus* on rheumatism, inflamed joints and rheumatic fever improves the pain and swelling in people. The natives of Alberta use *A. calamus* for prevention of headache, toothache, hangover and as a

disinfectant for teeth. Further, in Western herbal medicine, the plant is mainly employed for gastrointestinal related problems like bloating, gas, colic and poor digestive function. In China, it is used by ethnic groups to cure constipation, digestive problems and for decreasing swelling. The plant is also found to reduce the stress-induced suppression of immunity and improves the immunity in experimental rats. The pharmacological studies have established numerous beneficial properties including anti-oxidant, anti-inflammatory, anti-cancer, anti-ulcer, anti-fungal, anti-allergic, anti-diabetic, anti-microbial, wound healing, neuroprotective, radioprotective, pesticidal, insecticidal and cardioprotective effects and others which are depicted in Fig. 2. The plant had a long antiquity and numerous ethnomedicinal, pharmacological and economic applications. Several medicinal practices allow to surpass diverse cultural barriers thereby gaining its widespread usage. Henceforth, considering and incorporating both ecological and socio-economic aspects is important when the demand of the products increased with respect to trade commodities and distant market [10, 11, 15, 16, 17, 18].

The recent publications indicate the growing interest in the potential of *A. calamus* and its main constituents as chemo preventive agent/s (Fig. 3). Various experimental investigations of *A. calamus* and its main constituents with cultured human malignant cell lines and animal models have confirmed antitumor and cancer preventive activities. The subsequent section provides a brief understanding into the anticancer properties of *A. calamus* and/or its bioactive phytochemicals (α - and (β)-asarone.

2. Main text

2.1. *In-vitro* anti-cancer properties of *A. calamus* or asarone

2.1.1. Effect of (β)-asarone in human glioblastoma U251 cells

The most common type of primary malignant brain tumor accounts for 82 % cases of malignant gliomas. Glioblastoma is characterized by rapid growth, enhanced angiogenesis and capacity for higher invasion. Although, the current combination therapy has doubled the survival rate in patients with glioblastoma but it remains enormously poor due to severe toxicity, drug resistance and high rates of recurrence [19, 20]. Qi




Fig. 1. Chemical structures of various constituents obtained from *A. calamus*.




Fig. 2. Schematic representation of various pharmacological activity of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)- and beta (β)-asarone).




Fig. 3. Number of publications per year on *A. calamus* and/or its bioactive phytochemicals asarones. The PubMed database (<https://www.ncbi.nlm.nih.gov/pubmed/>) was searched with the keywords “*Acorus calamus* and cancer” and “asarone and cancer”.

et al. studied the cytotoxic effect of (β)-asarone in human glioblastoma U251 cells. They studied the cell death by fluorescent staining using YO-PRO-1 and propidium iodide (PI), which revealed that the cells treated by (β)-asarone underwent apoptotic and necrotic death. A proteomic based strategy was carried out to characterize the U251 cells treated with or without (β)-asarone to clarify the differential protein targets. In total, seven up-regulated and nine down-regulated proteins

were identified by matrix assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) mass spectrometer. The identified proteins were analyzed by gene ontology (GO) based on cellular components, molecular function and biological processes. Among them, four important proteins namely heterogeneous nuclear ribonucleoprotein H1 (H), isoform CRA_b (hnRNP H1 isoform CRA b), heterogeneous nuclear ribonucleo-protein A2/B1, isoform CRA a (hnRNP A2/B1 isoform CRA

a), ubiquitin carboxyl-terminal hydrolase isozyme L1 and cathepsin D) were identified to potentially serve as the therapeutic targets. Finally, the changes in the protein alterations were correlated with the mRNA at the transcriptional level by semi-quantitative RT-PCR technique. These results indicated that hnRNP H1 may be involved in HER-2/neu-driven tumor proliferation, invasion and metastasis. Further, authors suggested that the hnRNP A2/B1 could be used as a biomarker for prediction of glioma progression and can act as a novel oncogene in glioblastoma. They concluded that (β)-asarone is effective as anti-tumor agent as it was shown to inhibit the expression of hnRNP H1, hnRNPA2/B1 and cathepsin D against brain tumor [21].

In another study carried by Li *et al.*, the effect and mechanisms of (β)-asarone against tumor invasion and epithelial–mesenchymal transition (EMT) were explored. The inhibitory effects of (β)-asarone on the migration of U251 cells (wound healing assay), suppression of the invasion of U251 cells (Boyden chamber invasion assay) and inhibition of the adhesion of U251 cells (Matrigel) was evaluated. Further the down-regulation of hnRNP A2/B1 oncogenic protein by (β)-asarone supports the study done by Qi *et al.* In conclusion, the results suggested that (β)-asarone inhibits invasion and EMT in human glioma U251 cells by suppressing splicing factor hnRNP A2/B1 [22]. The above study was further explored by Li *et al.* for the potential role of hnRNP A2/B1-mediated signaling pathway in the anti-glioma effect of (β)-asarone. They assessed the inhibitory effect of (β)-asarone on the cell viability of human glioma U251 cells by sulforhodamine B (SRB) assay and found it to be effective in a concentration and time dependent manner. Furthermore, the cell apoptosis was characterized with Annexin V/Pi staining by flow cytometry, where (β)-asarone induces cell

apoptosis rate and cell cycle arrest at the G₁ phase through modulation of p21, p27, cyclin D, cyclin E, CDK2 and Cdc25A. They also demonstrated that the ratio of Bcl-xS/Bcl-xL was enhanced by (β)-asarone in both mRNA and protein level by the inhibition of hnRNP A2/B1-mediated signaling pathway [23]. The P-glycoprotein (P-gp) is a major cause of tumors resistance to chemotherapeutic agents. The relationship between cell resistance and P-gp is crucial as many tumors overexpresses the P-gp gene multi drug resistance-1 (MDR1). Wang *et al.* suggested that (β)-asarone might contribute to the treatment by promoting Temozolomide's (TMZ) entry into the glioma cells and can inhibit the expression of P-gp and MDR1 mRNA better than single TMZ. This data was further supported by examining the expression of P-gp with different methods and all of the results showed that the expression of P-gp and MDR1 mRNA level decreased in the (β)-asarone, TMZ and co-administration groups, whereas the co-administration group showed better effect [24]. The above study was further continued by Wang *et al.* focusing on the effect of (β)-asarone induced cell death in U251 cells. They concluded that (β)-asarone can inhibit the progression of glioma U251 cells by arresting the cell cycle in G₀/G₁ phase and promoting autophagy possibly through P53/Bcl-2/Bcl-xL and P53/AMPK/mTOR signal transduction pathway [25] (Table 1; Figs. 4, 5, and 6).

2.1.2. Effect of (β)-asarone in human colorectal cancer

The incidence of the colorectal cancer (CRC) is the third most common type of cancer and a leading cause of cancer-related mortality in developed and developing countries [26]. The effectiveness of chemotherapeutic agents is often limited due to high occurrence of severe side effects and drug resistance. Hence, search for new treatment strategies

Table 1

In-vitro effect of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) on human cancer cell lines.

Cell lines	Treatment	Targets/Possible molecular events	Reference
Glioblastoma (U251 cells)	(β)-asarone (240 and 360 μM)	Apoptosis (YO-PRO-1 and PI staining). Inhibition of the expression of hnRNP H1, hnRNPA2/B1 and cathepsin D.	[21]
Glioblastoma (U251 cells)	(β)-asarone (30 and 60 μM)	Inhibition of the migration (Wound healing assay). Suppression of the invasion (Boyden chamber invasion assay). Inhibition of adhesion (Matrigel coated). ↓ epithelial–mesenchymal transition (EMT) via upregulation of E-cadherin and down-regulation of vimentin. Inhibition of the expression of hnRNP A2/B1 in a concentration and time-dependent way.	[22]
Glioblastoma (U251 cells)	(β)-asarone (60, 120, 240 and 480 μM)	↓ expression of matrix metalloproteinases (MMP-9) and p-STAT3. Apoptosis (Annexin V/Pi staining). Cell cycle arrest at G ₁ phase. Inhibition of the expression of hnRNP A2/B1 in a concentration and time-dependent way. Ratio of Bcl-xS/Bcl-xL ↑ by (β)-asarone in both mRNA and protein level by the inhibition of hnRNP A2/B1-mediated signaling pathway. Promoted the activation of the death receptor proteins TRAIL and FasL. Cleavage of caspase 8 and caspase 3. ↑ in the expression of cleaved-BID and cellular protein cytochrome C. ↑ in the expression of cell cycle related proteins p21 and p27 and ↓ in expression of cyclin D, cyclin E, Cdc25A and CDK2.	[23]
Glioblastoma (U251 cells)	(β)-asarone (360 μM)	↓ in the cell proliferation in the medicated groups (CCK-8 assay). ↓ in the expression of P-glycoprotein (P-gp) in the medicated groups.	[24]
Glioblastoma (U251 cells)	(β)-asarone (360 μM)	↓ in the expression of multi drug resistance-1 (MDR1) mRNA expression. ↓ in the cell proliferation in the medicated groups (CCK-8 assay). Cell cycle arrest at G ₀ /G ₁ phase. Formation of autophagosome (double-membrane autophagosomes and single-membrane autolysosomes) was observed. ↑ in the expression of autophagic markers like Beclin-1 and LC3-II/I and ↓ in the expression of p62. ↑ in the expression of P53 mRNA, P53, AMPK and pAMPK and ↓ in the expression of Bcl2, mTOR and pmTOR.	[25]
Colon cancer (LoVo cells)	(β)-asarone (200 and 400 μM)	↓ in the rate of cell viability (MTT assay). Ultra-structure changes of the LoVo cells indicating apoptosis (Hoechst staining). Apoptosis (Annexin V-FITC/PI staining). Down-regulation of mitochondrial membrane potential (MMP). ↑ proapoptotic proteins (Bax expression) and ↓ antiapoptotic regulators (Bcl-2, Bcl-xL and survivin)	[27]

(continued on next page)

Table 1 (continued)

Cell lines	Treatment	Targets/Possible molecular events	Reference
Colorectal cancer (HT29 and SW480 cells)	(β)-asarone (0, 10, 30 and 100 nM)	↓ in the Bcl-2/Bax ratio and ↑ of the executor apoptosis enzyme caspase-9 and caspase-3 cascades. ↓ in the cell proliferation (MTT assay). Induces cell senescence (SA- β -Gal activity). ↑ in the levels of lamin B1, as well as p53, p21 and p15.	[28]
Colon adenocarcinoma (Caco-2 cells)	(α)- and (β)-asarone (30 μ g/ml)	Enhancement of the vincristine induced cytotoxicity to cells (MTT assay). ↑ in the intracellular accumulation of Rhodamine 123 (Rh123) uptake and inhibited Rh123 efflux in Caco-2 cells. ↓ expression of multi drug resistance-1 (MDR1) gene and P-glycoprotein (P-gp).	[29]
Gastric cancer (SGC-7901, BGC-823 and MKN-28 cells)	(β)-asarone (0.12 and 0.24 mM)	↓ in the cell viability (MTT assay). Apoptosis (Annexin V-FITC/PI staining). Ultra-structure changes of the cells indicating apoptosis (Hoechst 33342 staining). Inhibited the migration, invasion and adhesion (Wound-healing, transwell and matrix-cell adhesion assay). Activates caspase-3, 8 and 9 levels. ↑ proapoptotic proteins (Bax and Bak expression) and ↓ antiapoptotic regulators (Bcl-2, Bcl-xL and surviving activity). ↑ in the expression of RECK, E-cadherin and ↓ the expression of MMP-2, MMP-9, MMP-14 and N-cadherin.	[30]
Gastric adenocarcinoma (AGS cells) Fibroblast (HSkMC cells)	Alcoholic extracts of <i>A. calamus</i> (15, 30, 60, 120, 240 and 480 μ g/ml)	Anti-proliferative effects (MTT assay). Cell cycle arrest at G ₁ phase. Inhibition of formation of tube-like structures confirming anti-angiogenic property (Tube formation assay). Down-regulation of Oct4 and Nucleostemin.	[31]
Prostate cancer (LNCaP cells)	Ethanol extract of <i>A. calamus</i> (250, 500 and 750 μ g/ml)	↓ in the cell viability (XTT assay). Induces apoptotic cell death (↑ in cleaved poly (ADP-ribose) polymerase/ PARP). ↓ in VEGF mRNA expression.	[33]
Prostate cancer (PC-3 cells) Neuroblastoma (IMR-32 cells) Cervical cancer (HeLa cells) Synovial cancer (SW982 cells) Breast cancer (MCF-7 cells)	Nitro derivatives of (β)-asarone (1.56–200) μ M	↓ in the cell viability (MTT assay).	[34]
Macrophage cancer (P338D1 and J774 cells) T cell lymphoma (A20 cells) B cell lymphoma (WEHI-279 cells)	Novel lectins from <i>Acorus</i> species (1.0–10) μ g/ml	↓ in the cell viability (³ H-thymidine incorporation).	[35]
Cervical cancer (HeLa cells) Adenocarcinoma (A549 cells)	Green silver nanoparticles synthesized from <i>A. calamus</i> (25, 50, 75, 100, 125, 150, 175 and 200 μ g/ml)	Anti-proliferative effect (% inhibition of cell proliferation through MTT assay). Apoptotic cell death (Acridine orange/ethidium bromide (AO/EB) and annexinV-Cy3 staining and TUNEL assay). Nuclear changes as fragmentation and condensation (propidium iodide (PI) and 4', 6-diamidino-2-phenylindole dilactate (DAPI) staining).	[36]
Breast carcinoma (MDA-MB-435S cells) Liver carcinoma (Hep3B cells)	Aqueous and methanolic extracts of <i>A. calamus</i> (15.625, 31.25, 62.5 and 125 μ g/ml)	↓ in the percentage mitotic index of root tip cells and cell viability (<i>Allium cepa</i> root tip and XTT assay).	[41]

Abbreviations: hnRNP A2/B1: Heterogeneous nuclear ribonucleoproteins; TRAIL: TNF-related apoptosis-inducing ligand; FasL: Fas ligand; CCK-8: Cell counting kit 8; Oct-1, 4: Octamer-binding protein-1,4; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling.

for CRC is ongoing since several decades. In a study undertaken by Zou *et al.*, the anticancer properties by upregulation of caspases activity through the mitochondrial pathway in human colon cancer cells was determined. The (β)-asarone showed dose- and time-dependent cell viability in human LoVo colon cancer cells and induced cell apoptosis by annexin V, which was estimated by fluorescein isothiocyanate/propidium iodide assay by flow cytometry. Further, the relative mRNA expression levels of pro- and anti-apoptotic factors were determined particularly focusing on the change of mitochondrial membrane potential (MMP) via activation of caspase-9, caspase-3 and the ratios of Bcl-2/Bax and Bcl-xL/Bax [27]. The suppression of cellular senescence is one of the features of colorectal cancer and has been linked with aging. One of the factors involved in cellular senescence is the lamin proteins. The lamin B1 gene is suppressed in primary human and murine cell lines when they endure senescence after DNA damage. In another study Liu *et al.* establish that the (β)-asarone effectively targets cell senescence via lamin protein leading to cell survival. Human colorectal cell lines HT29 and SW480 were treated with (β)-asarone and it had a time- and dose-dependent effect on cell viability. Finally, authors

concluded that (β)-asarone inhibits colorectal carcinogenesis by inducing cellular senescence through lamin B1 gene. The increased lamin B1 promotes p53 and p21 expression, and recruits Oct-1 onto nuclear envelope and prevents binding to the p15 promoter, upregulating p15 [28]. Beside that, multiple drug resistance (MDR) is one of the major barriers in cancer chemotherapy. Meng *et al.* reported that both (α)- and (β)-asarone significantly enhanced the vincristine induced cytotoxicity in human colon adenocarcinoma (Caco-2) cells by enhancing the influx and inhibiting a transmembrane efflux pump (P-Glycoprotein) functions in a concentration dependent manner. Further, it was found that the (α)- and (β)-asarone cause the reduction in P-gp expression and P-gp mRNA in cells [29] (Table 1; Figs. 4, 5, and 6).

2.1.3. Effect of (β)-asarone/alcoholic extracts of *A. calamus* in human gastric cancer cells

Gastric or stomach cancer is the fourth most common gastrointestinal malignancy. The primary therapy, surgery combined with chemotherapy may achieve satisfactory results, but is not useful for advanced stage of gastric cancer. A study was undertaken by Wu *et al.* to explore the impact




Fig. 4. The possible site of action of beta (β) asarone in apoptosis, cell proliferation and growth. (A) The (β)-asarone regulates the levels of the key proteins involved in the cell death and mitochondrial apoptosis pathway. (β)-asarone results in enhancement of the ratio of Bcl-xS/Bcl-xL via inhibition of hnRNP A2/B1-mediated signaling pathway, which may be correlated with (β)-asarone-induced apoptosis. On the other hand, the increased expression of cleaved-caspase 3, 8 and 9 along with the activation of the death receptor proteins TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL), it results in the induction of apoptosis. (B) (β)-asarone induced the cell cycle arrest at G₀/G₁ phase through the up-regulation of cell cycle related proteins as p21 and p27 and down-regulation of cyclin D, cyclin E, Cdc25A and CDK2. [Possible site of action of (β)-asarone as observed in glioblastoma (U251 cells), colon cancer (LoVo cells), colorectal cancer (HT29 and SW480 cells), gastric cancer (SGC-7901, BGC-823 and MKN-28 cells), gastric adenocarcinoma (AGS cells), fibroblast (HsKMC cells) and prostate cancer (LNCaP cells)].




Fig. 5. The possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)- and beta (β)-asarone) in tumor cell metastasis, invasion, migration and angiogenesis. (A) The (β)-asarone decreases the expression of epithelial-mesenchymal transition (EMT) through upregulation of E-cadherin and down-regulation of vimentin or N-cadherin via inhibition of the expression of hnRNP A2/B1-mediated signaling pathway, thereby suggesting (β)-asarone may block the process of EMT process in cancerous cells. (B) Matrix metalloproteinases (MMPs) are involved in the hnRNP A2/B1-related cancer invasion, migration and metastasis. *A. calamus* and/or asarone suppresses the expression of matrix metalloproteinases (MMP-2, 9 and 14) and vascular endothelial growth factor (VEGF) thereby underlying the inhibitory effect on invasion, migration and metastasis. [Possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)- and beta (β)-asarone) as observed in glioblastoma (U251 cells), colon cancer (LoVo cells), gastric cancer (SGC-7901, BGC-823 and MKN-28 cells) and prostate cancer (LNCaP cells)].

of (β)-asarone on human gastric cancer cells along with establishment of the possible mechanism. The effect of (β)-asarone was studied on three types of differentiated human gastric cancer cell lines such as SGC-7901, BGC-823 and MKN-28. The (β)-asarone inhibits the proliferation of gastric cancer cells in a dose-dependent manner and induces early apoptosis. Further, transwell and wound-healing assays reveals that (β)-asarone inhibited the migration of BGC-823 cells in a concentration-dependent manner. Finally, mRNA and protein expression changes for studying the mechanism of action on the apoptosis of gastric cancer cells was carried out with western blotting and RT-PCR technique. This study clearly depicts that (β)-asarone inhibited the gastric cancer cell growth by upregulating the expression of caspases, proapoptotic proteins, RECK, E-cadherin and by downregulating the expression of antiapoptotic proteins, matrix metalloproteinases and N-cadherin [30]. Haghighi *et al.* investigated the anti-cancer and anti-angiogenic activity of the alcoholic extracts and essential oil of *A. calamus* on gastric cancer cell line (AGS) and compared with primary human fibroblast cell line (HsKMC). The growth inhibitory effects of the extracts and essential oil have a concentration and time dependent significant reduction in the proliferation of AGS cells and cell cycle arrest at G₁ phase. Further, the tube formation assay showed anti-angiogenic effects of the extracts and essential oil. It was finally supported by the downregulation of Oct4 and Nucleostemin after treatment of the cells with the extracts as confirmed by flowcytometry

and quantitative RT-PCR [31] (Table 1; Figs. 4, 5, and 6).

2.1.4. Effect of (β)-asarone/ethanolic extracts of *A. calamus* in human prostate cancer cells

Prostate cancer is the most commonly diagnosed cancer and remains the third-leading cause of cancer death in men [32]. The pro-angiogenic factor - vascular endothelial growth factor-A (VEGF-A) is believed to be the single most significant angiogenic factor in prostate cancer for accelerating all stages of angiogenesis making it a desirable target. A recent study suggested that the ethanolic extract of *A. calamus* root possesses a dose and time dependent anticancer, apoptotic and anti-angiogenic activities on prostate cancer cell culture. Koca *et al.* examined whether ethanolic extract of *A. calamus* marks the survival and apoptosis as well as inhibits the angiogenesis. The effect of *A. calamus* extract on the cell viability showed a dose-response relationship of cell survival. The Poly-(ADP-ribose) polymerase (PARP) cleavage involved in the apoptotic process was found to be at higher expression in *A. calamus* extract treated cells. It was also supported by the suppression of mRNA expression of the pro-angiogenic factor VEGF-A in LNCaP cells treated with the *A. calamus* extract [33]. Shenvi *et al.* reported the anti-cancer assay of nitro derivatives of (β)-asarone using PC-3 (prostate cancer) cell line along with four other different types of human cancer cell lines by using MTT assay. The nitration derivative compounds of (β)-asarone




Fig. 6. The possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) in cellular senescence and autophagy. It inhibits carcinogenesis by inducing cellular senescence through activation of lamin B1. Elevated lamin B1 promotes p53 and p21 expression, and recruits Oct-1 or 4 onto nuclear envelope and prevents binding to the p15 promoter, upregulating p15. On the other hand, activated p53 inhibits Bcl-2, which induces cell apoptosis in the cell cycle. Further autophagy is promoted through up-regulation of autophagy related proteins (Beclin-1 and LC3-II/I) and down-regulation of p53 related proteins (mTOR, Bcl-2). Atg: Autophagy related gene; mTOR: Mammalian target of rapamycin; Oct-1/4: Octamer-binding protein-1,4; LC3: Microtubule-associated proteins 1A/1B light chain 3B. [Possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) as observed in glioblastoma (U251 cells), colorectal cancer (HT29 and SW480 cells), fibroblast (HSKMC cells) and gastric adenocarcinoma (AGS cells)].

exhibited an increase in activity compared to (β)-asarone confirming its cytotoxic activity in all the cell lines [34] (Table 1; Figs. 4 and 5).

2.1.5. Effect of novel lectins from *Acorus species* in murine cancer cells

Lectins, the major proteins of many monocotyledonous plants are polyclonal activators towards human lymphocytes. In a study performed by Bains *et al.*, they reported two novel lectins derived from the rhizomes of *A. calamus* and *A. gramineus* possessing significant mitogenic activity towards human lymphocytes and inhibitory activity towards murine macrophage cancer cell lines. They employed macrophage cancer cell lines (P338D1 and J774), T cell lymphoma (A20) and B cell lymphoma (WEHI-279) for MTT assay to study the inhibitory activity of the novel lectins. Both the novel lectins (*A. calamus* and *A. gramineus*) showed inhibitory activity towards the murine cancer cell lines as measured by ^3H -thymidine incorporation confirming its inhibitory potential [35] (Table 1).

2.1.6. Effect of green silver nanoparticles synthesized from *A. calamus* rhizome extract in human cervical cancer (HeLa) and lung adenocarcinoma (A549) cell lines

The use of the inert metals such as gold, silver, and platinum in the field of nanomedicine is gaining interest for synthesizing metallic nanoparticles having high therapeutic potential for various uses. Green synthesis of silver nanoparticles using various medicinal plants have shown to exhibit *in-vitro* anticancer activities. Keeping view of the above evidences, Nakkala *et al.* carried out the *in-vitro* cytotoxic effects of green silver nanoparticles synthesized from *A. calamus* rhizome extract

(ACAgNPs) in human cervical cancer (HeLa) and lung adenocarcinoma (A549) cell lines. The anti-proliferative effect expressed as % inhibition of cell proliferation through MTT assay were found within the acceptable concentration of 100 mg/L. The apoptotic cell death was confirmed further through acridine orange/ethidium bromide (AO/EB) and annexinV-Cy3 staining techniques being supported by the nuclear changes (fragmentation and condensation) through staining with propidium iodide (PI) and 4', 6-diamidino-2-phenylindole dilactate (DAPI) and flow cytometry. Collectively, all these findings suggested the cytotoxic activity of green silver nanoparticles synthesized with *A. calamus* rhizome extract [36] (Table 1).

2.2. In-vivo anti-cancer effect of *A. calamus*

Beside *in-vitro* investigation, *in-vivo* studies provided the evidence supporting that *A. calamus* and/or its bioactive phytochemicals asarone have potential anti-cancer pharmacological effect. Here, we discussed the detailed evidence about the anti-cancer effect of *A. calamus* and/or its bioactive phytochemicals asarone.

Zou *et al.* evaluated the anti-cancer property of (β)-asarone in nude mice through LoVo cancer xenografts model. The experimental animals treated with (β)-asarone at 50 mg/kg/d b.w. concentration suppressed the tumor volume significantly in comparison to placebo controls. Further, to determine that the tumors in the (β)-asarone treated group were inhibited through apoptosis, the isolated tumors was subjected to TUNEL assay. It was confirmed that fragmentation of DNA was observed in the growth-inhibited tumors for the nude mice suggesting the

Table 2*In-vivo* anti-cancer effect of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).

Model/Animal used	Treatment	Targets/Effects/Possible molecular events	Reference
LoVo cancer xenograft model (Nude mice)	(β)-asarone (50 mg/kg/d b.w.; p.o.)	Suppression of the tumor volume. Apoptosis as confirmed by fragmentation of DNA in the growth-inhibited tumors (TUNEL assay).	[27]
DMH (1, 2-dimethyl hydrazine) induced colorectal cancer (Crj: CD-1 (ICR) mice)	(β)-asarone (50, 100 and 200 μ g/kg/d b.w.; p.o.)	Reduction in the incidence and number of tumor formation. Induction of senescence in human colorectal cancer via activation of lamin B1 by promoting the tumor protein (p53, p21) expressions.	[28]
Human colorectal cancer (SW480 and HT-29 xenograft model) (BABL/c nude mice)	(β)-asarone (50, 100 and 200 μ g/kg/d b.w.; i.v.)		
Diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) (wistar Albino rats)	(β)-asarone (25 μ g/kg/d b.w.; p.o.)	↓ in the levels of serum liver biomarkers (ALT, AST, ALP, TB and DB). ↓ in the levels of cancer biomarkers (DNA, RNA and AFP).	[37]
Glioma U251 tumor xenograft model (Nude mice)	(β)-asarone (25 and 50 mg/kg/d b.w.; p.o.)	Suppression of the tumor growth. ↑ in the apoptotic rate (TUNEL assay). ↑ level of apoptotic proteins (cleaved caspase-3 and p27). ↓ in the expression of hnRNP A2/B1 and CKD2. ↑ in ratio of Bcl-xS/Bcl-xL.	[23]
Dalton's ascites lymphoma induced tumor (swiss Albino mice)	Methanolic extracts of <i>A. calamus</i> (100 and 200 mg/kg/d b.w.; i.p.)	↑ in the liver antioxidant enzyme level of SOD, CAT, GPx, GSH, Vitamin C and E. ↑ in the kidney antioxidant enzyme level of SOD, CAT, GPx, GSH, LPO and Vitamin E. ↓ in the tumor volume. ↓ in the levels of serum liver biomarkers (ALT, AST and ALP).	[42, 43, 44]

Abbreviations: b.w.: body weight; d: day; p.o.: per oral route; i.v.: intravenous route i.p.: intraperitoneal route.

Table 3*In-vitro* and *in-vivo* anti-oxidant effect of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).

Model/Animal used/Cell lines	Treatment	Targets/Effects/Possible molecular events	Reference
<i>In-vitro</i> anti-oxidant activity	Essential oils of <i>A. calamus</i> (5–25) μ L/mL	The oils isolated from the rhizome and leaves in all the different seasons exhibited antioxidant activity as confirmed by 2, 2-diphenyl picryl hydrazyl (DPPH), reducing power (RP) and chelating properties of Fe ²⁺ .	[45]
<i>In-vitro</i> anti-oxidant and free radical scavenging activity	Aqueous extracts of <i>A. calamus</i> (25–400) μ g/mL	Results showed that the aqueous extracts have a potential free radical scavenging activity as confirmed by DPPH, nitric oxide, superoxide radical, ferrous chelation, RP and phosphomolybdenum assay.	[46]
<i>In-vitro</i> anti-oxidant activity	(α)-asarone (10–100) μ g/mL	It exhibited a dose-dependent DPPH radical-scavenging, RP, superoxide radical and hydroxyl radical scavenging activity.	[47]
Ischemia-induced brain infarction oxidative stress (wistar rats)	(β)-asarone (10, 20 and 30 mg/kg/d b.w.; p.o.)	↑ in the levels of reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione S transferase (GST) and catalase (CAT) activity in the hippocampus. ↓ in the level of lipid peroxidation (LPO) content in the hippocampus.	[48]
Senescence- accelerated prone 8 (SAMP-8) (Alzheimer's mediated oxidative stress) (mice)	(β)-asarone (34 mg/kg/d b.w.; p.o.)	(β)-asarone did not affect superoxide dismutase (SOD) activities in brain and malondialdehyde (MDA) level in serum.	[49]
High-fat diet (HFD) induced metabolic abnormalities oxidative stress (wistar rats)	(β)-asarone (12.5, 25, and 50 mg/kg/d b.w.; p.o.)	↑ levels of GSH and ↓ levels of MDA in liver homogenate.	[50]
Noise stress-induced oxidative stress in brain (wistar rats)	(α)-asarone (3, 6, and 9 mg/kg/d b.w.; i.p.)	↓ in the levels of SOD and LPO content in the brain. ↑ in the levels of CAT, GPx, GSH, Vitamin C, E and protein thiols in the brain.	[51]
Brain enzymatic antioxidant activities (Swiss OF1 mice)	(α)-asarone (100 mg/kg/d b.w.; i.p.)	↑ in the levels of GPx and GR in the three areas of brain (cortex, striatum and hippocampus). SOD activity was unaffected in cortex and ↑ in striatum and hippocampus.	[52]
γ -radiation induced alterations in oxidative stress (swiss Albino mice)	(α)-asarone (50 mg/kg/d b.w.; p.o.)	↑ in the levels of GSH, SOD, GPx and CAT in brain and kidney homogenate.	[53]
Scopolamine induced cognitive deficits mediated oxidative stress (ICR mice)	(α)-asarone (3, 10 and 30 mg/kg/d b.w.; i.p.)	↓ in the levels of MDA and SOD in both areas of the brain (cerebral cortex and hippocampus).	[54]
Noise stress-induced oxidative stress in brain (wistar Albino rats)	(α)-asarone (9 mg/kg/d b.w.; i.p.)	↓ in the levels of SOD and LPO content in hippocampus. ↑ in the levels of CAT, GPx, GSH, Vitamin C and E in hippocampus.	[55]
Dalton's ascites lymphoma induced tumor (swiss Albino mice)	Methanolic extracts of <i>A. calamus</i> (100 and 200 mg/kg/d b.w.; i.p.)	↑ in the liver antioxidant enzyme level of SOD, CAT, GPx, GSH, Vitamin C and E. ↑ in the kidney antioxidant enzyme level of SOD, CAT, GPx, GSH, LPO and Vitamin E.	[42, 43, 44]

Abbreviations: b.w.: body weight; d: day; p.o.: per oral route; i.v.: intravenous route i.p.: intraperitoneal route.

apoptotic changes [27]. Furthermore, another study carried by Liu *et al.* revealed that (β)-asarone treatment reduced the incidence and number of tumor formation against the genotoxic colonic chemical carcinogen DMH (1, 2-dimethyl hydrazine) in Crj: CD-1 (ICR) mice. Moreover, the reduction in the tumor volume in xenografts model of colorectal cancer in BABL/c nude mice through administration of SW480 or HT-29 cells was observed in the (β)-asarone treated group. It was further supported by data that (β)-asarone induced senescence in human colorectal cancer via activation of lamin B1 by promoting the tumor protein (p53, p21) expressions [28]. Our earlier study reported that (β)-asarone treatment

protects the rats from the diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) which was confirmed by the changes in the levels of the liver function markers and cancer bio-marker (alpha-fetoprotein) and supported by histopathological changes [37]. Recently, it was reported that (β)-asarone inhibits tumor growth and induces apoptosis in U251 tumor xenograft nude mice model. The tumor was harvested for apoptosis with a standard *in-situ* terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and found that the apoptotic rate in the tumors significantly enhanced in (β)-asarone treatment group when compared with that of vehicle control.

Table 4

Acute toxicity studies of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).

Animal species/strain/ gender	Median lethal dose (LD ₅₀)		Reference
	(α)-asarone	(β)-asarone	
BALB/c mice (male)	245.2 mg/kg b.w.; i.p.	–	[39]
Rat	–	1010 mg/kg b.w.; p.o.	[40]
Mice	–	184 mg/kg b.w.; i.p.	[40]
Swiss mice (male)	>1000 mg/kg b.w.; p.o.	–	[56]
BALB/c mice (both gender)	–	1.56 g/kg b.w.; i.v.	[28]

Abbreviations: b.w.: body weight; p.o.: per oral route; i.v.: intravenous route i.p.: intraperitoneal route.

Furthermore, the expression of apoptotic proteins in tumor tissues was observed by the increase level of cleaved caspase-3 in the treated group. A dose-dependent decrease of the expression of hnRNP A2/B1 and CKD2, increase ratio of Bcl-xS/Bcl-xL and along with that increase expression of p27 was observed for the treated group when compared with that of the vehicle group. Finally, the results obtained in this study demonstrates that (β)-asarone -induced apoptosis and cell cycle arrest of U251 cells may be linked to the suppression of hnRNPA2/B1-mediated signaling pathway [23] (Table 2).

2.3. Anti-oxidant properties of *A. calamus* or asarone

Anti-oxidants are known free radical scavengers that allow the cells to rejuvenate from cellular damage by neutralizing the highly reactive oxygen compounds [38]. The anti-oxidant effect of *A. calamus* or asarone was reported by different *in-vitro* and *in-vivo* studies (Table 3). The bioactive compounds of the plant showed up/down regulation of certain endogenous enzymatic and non-enzymatic parameters which ultimately proves their ability to scavenge free radicals. Various reports suggest that the *A. calamus* or asarone are effective against number of oxidative stress models viz., ischemia-induced brain infarction oxidative stress, γ -radiation induced alterations in oxidative stress, noise stress-induced oxidative stress in brain etc.

2.4. Toxicity profile of *A. calamus* or asarone

In acute toxicity studies, *A. calamus* and/or its bioactive phytochemicals asarone were found to be safe at lower doses as summarized in Table 4. An acute toxicity study of (α)-asarone (150, 200, 250, 300 and 350 mg/kg b.w.; i.p.) was undertaken by Morales *et al.* in male BALB/c mice for 14 days. The most frequent clinical signs observed among the animals were ptosis, ataxia, piloerection and dyspnea [39]. In another study Liu *et al.* tested the effect of (β)-asarone (0.5, 0.75, 1, 1.25, 1.5, 1.75 and 2 g/kg b.w.; i.v.) on BALB/c mice to evaluate the preliminary toxicity. They reported that the animals that received (β)-asarone did not exhibit any behavior change within 24 h of treatment. Further they performed a long-term toxicity test for 90 days at the dosages of 10, 20 and 50 mg/kg/d. Results showed a dose-dependent toxicology with increase in number of white blood cells (WBC) and decrease in number of red blood cells (RBC) at 10 mg/kg. Additionally, the levels of serum K⁺ decreased at the dose of 20 mg/kg and Cl[−] increased in 50 mg/kg treated mice [28].

In sub-acute toxicity study, Sprague Dawley rats treated with (β)-asarone (100 mg/kg/d b.w.; i.p.) exhibited characteristic weight loss and decreased food consumption. Additionally, the weight of heart and thymus were reduced and weight of adrenals was increased. Furthermore, there was no significant changes in haematological and biochemical parameters indicating hepatotoxicity [40]. In a two-year

feeding study, Osborne-Mendel fed the male rats with a diet containing either (β)-asarone or calamus oil (400, 800 or 2000 mg/kg). The rats developed an increased incidence of leiomyosarcomas in small intestine. Microscopic analysis revealed cardiac atrophy, fat infiltration and fibrosis in heart of the animals. Further, rats fed with the Jammu oil of calamus (0, 50, 100 or 5000 mg/kg) for two years developed early mortality, liver and heart lesions at a dose of 5000 mg/kg [40].

3. Conclusions

Cancer is one of the growing health problems worldwide, posing a threat to human social and economic conditions. Regardless of the advanced treatment modality available for the treatment of cancer such as chemotherapy, surgical resection, radiotherapy and phototherapy, the survival rate has not been enhanced because of its high recurrence, toxic side-effects and metastasis rate. Hence, on-going efforts in search of anti-cancer agents derived from natural sources with low toxicity and greater enhancement of survival is gaining interest among many researchers. Based on the available literature, it appears that natural phytochemicals obtained from the plants, have been explored for their anti-cancer activity. *Acorus calamus*, commonly known as the 'sweet flag' has a rich history in the Indian and Chinese traditional medicine and found to be a popular remedy with great efficacy for various diseases. The information presented in this review focuses and summarizes the anti-cancer activity of *A. calamus* and/or its bioactive phytochemicals asarones (alpha (α)-and, beta (β)-asarone) including the underlying molecular mechanisms. Collectively, the mechanism underlying cancer chemo-prevention of *A. calamus* and/or its bioactive phytochemicals asarone includes variation of all kinds of cancer hallmarks. These includes regulation of cell proliferation and cell cycle arrest, induction of apoptosis, inhibition of angiogenesis as modulated via different signal transduction pathways. Still, extensive *in-vivo* studies are necessary using various models to understand the molecular mechanism behind the pharmacological activity of the bioactive phytochemicals derived from *A. calamus*. We believe that the evidence presented in this article could be a possible source for researchers to conduct future studies pertaining to *A. calamus* and/or its bioactive phytochemical asarone for cancer chemoprevention.

Declarations

Author contribution statement

All authors listed have significantly contributed to the development and the writing of this article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

Authors acknowledge the support of The Principal, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka, India for extending the facilities to prepare this article.

References

- [1] A. Fundytus, et al., Delivery of global cancer care: an international study of medical oncology workload, *J. Glob. Oncol.* (2017) 1–11. JGO1700126.
- [2] P.E. Goss, et al., Challenges to effective cancer control in China, India, and Russia, *Lancet Oncol.* 15 (5) (2014) 489–538.
- [3] M.K. Mallath, et al., The growing burden of cancer in India: epidemiology and social context, *Lancet Oncol.* 15 (6) (2014) e205–e212.
- [4] A. Mohan, et al., Combinations of plant polyphenols and anticancer molecules: a novel treatment strategy for cancer chemotherapy, *Anti Cancer Agents Med. Chem.* 13 (2) (2013) 281–295.
- [5] S.B. Rajput, et al., An overview on traditional uses and pharmacological profile of *Acorus calamus* Linn. (Sweet flag) and other *Acorus* species, *Phytomed: Int. J. Phytother. Phytopharm.* 21 (3) (2014) 268–276.
- [6] Z.J. Wang, et al., Identification of both GABA-A receptors and voltage-activated Na⁺ channels as molecular targets of anticonvulsant alpha-asarone, *Front. Pharmacol.* 5 (2014) 40.
- [7] C. Huang, et al., Alpha-asarone from *Acorus gramineus* alleviates epilepsy by modulating A-type GABA receptors, *Neuropharmacology* 65 (2013) 1–11.
- [8] R. Balakumbahan, et al., *Acorus calamus*: an overview, *J. Med. Plants Res.* 4 (25) (2010) 2740–2745. Available at: <http://www.academicjournals.org/app/webroot/article/article1380712717.Balakumbahan%20et%20al.pdf>.
- [9] R.V. Lansdown, *Acorus calamus*. The IUCN Red List of Threatened Species, e. T168639A43116307, 2014. Available at: (Accessed 28 June 2018).
- [10] V. Sharma, et al., *Acorus calamus* (The Healing Plant): a review on its medicinal potential, micropropagation and conservation, *Nat. Prod. Res.* 28 (18) (2014) 1454–1466.
- [11] R. Singh, et al., Pharmacological properties and ayurvedic value of Indian buch plant. (*Acorus calamus*): a short review, *Adv. Biol. Res.* 5 (3) (2011) 145–154. Available at: <https://pdfs.semanticscholar.org/1083/b32c25ce2afdd8fbca3d72137b93eb23a89.pdf>.
- [12] A. Muthuraman, N. Singh, Acute and sub-acute oral toxicity profile of *Acorus calamus* (Sweet flag) in rodents, *Asian Pac. J. Trop. Biomed.* 2 (2) (2012) S1017–S1023.
- [13] S. Pandit, et al., Metabolism mediated interaction of alpha-asarone and *Acorus calamus* with CYP3A4 and CYP2D6, *Fitoterapia* 82 (3) (2011) 369–374.
- [14] K.M. Hanson, et al., Rapid assessment of beta-asarone content of *Acorus calamus* by micellar electrokinetic capillary chromatography, *Electrophoresis* 26 (4–5) (2005) 943–946.
- [15] H. Shu, et al., Ethnobotany of *Acorus* in China, *Acta Soc. Bot. Pol.* 87 (2) (2018) 3585.
- [16] A.D. Khwairakpam, et al., *Acorus calamus*: a bio-reserve of medicinal values, *J. Basic Clin. Physiol. Pharmacol.* 29 (2) (2018) 107–122.
- [17] H. Imam, et al., Sweet flag (*Acorus calamus* Linn.): an incredible medicinal herb, *Int. J. Green Pharm.* 7 (4) (2013) 288–296.
- [18] H.N. Sarjan, et al., The protective effect of the vacha rhizome extract on chronic stress-induced immunodeficiency in rat, *Pharm. Biol.* 55 (1) (2017) 1358–1367.
- [19] A. Omuro, L.M. DeAngelis, Glioblastoma and other malignant gliomas: a clinical review, *J. Am. Med. Assoc.* 310 (17) (2013) 1842–1850.
- [20] G.F. Woodworth, et al., Emerging insights into barriers to effective brain tumor therapeutics, *Front. Oncol.* 4 (2014) 126.
- [21] H. Qi, et al., Proteomic analysis of beta-asarone induced cytotoxicity in human glioblastoma U251 cells, *J. Pharm. Biomed. Anal.* 115 (2015) 292–299.
- [22] L. Li, et al., β -Asarone inhibits invasion and EMT in human glioma U251 cells by suppressing splicing factor HnRNP A2/B1, *Molecules* 23 (3) (2018) E671.
- [23] L. Li, et al., β -Asarone induces apoptosis and cell cycle arrest of human glioma U251 cells via suppression of HnRNP A2/B1-mediated pathway *in vitro* and *in vivo*, *Molecules* 23 (5) (2018) E1072.
- [24] N. Wang, et al., β -Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1, *Biomed. Pharmacother.* 90 (2017) 368–374.
- [25] N. Wang, et al., β -asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bcln-1 and P53/AMPK/mTOR pathways in human glioma U251 cells, *J. Cell. Physiol.* 233 (3) (2018) 2434–2443.
- [26] R.L. Siegel, et al., Cancer statistics, *CA. Cancer J. Clin.* 65 (1) (2015) 5–29.
- [27] X. Zou, et al., Beta-asarone induces LoVo colon cancer cell apoptosis by up-regulation of caspases through a mitochondrial pathway *in vitro* and *in vivo*, *Asian Pac. J. Cancer Prev.* 13 (10) (2012) 5291–5298.
- [28] L. Liu, et al., β -Asarone induces senescence in colorectal cancer cells by inducing lamin B1 expression, *Phytomedicine* 20 (6) (2013) 512–520.
- [29] X. Meng, et al., Reversing P-glycoprotein-mediated multidrug resistance *in vitro* by α -asarone and β -asarone, bioactive cis-trans isomers from *Acorus tatarinowii*, *Biotechnol. Lett.* 36 (4) (2014) 685–691.
- [30] J. Wu, et al., β -Asarone inhibits gastric cancer cell proliferation, *Oncol. Rep.* 34 (6) (2015) 3043–3050.
- [31] S.R. Haghighi, et al., Anti-carcinogenic and anti-angiogenic properties of the extracts of *Acorus calamus* on gastric cancer cells, *Avicenna J. Phytomed.* 7 (2) (2017) 145–156.
- [32] M.S. Litwin, H.J. Tan, The diagnosis and treatment of prostate cancer: a review, *J. Am. Med. Assoc.* 317 (24) (2017) 2532–2542.
- [33] H.B. Koca, et al., Effects of *Acorus calamus* plant extract on prostate cancer cell culture, *Anatolian J. Bot.* 2 (1) (2018) 46–51.
- [34] S. Shenvi, et al., Nitro derivatives of naturally occurring β -Asarone and their anticancer activity, *Int. J. Med. Chem.* 2014 (2014) 835485.
- [35] J.S. Bains, et al., Novel lectins from rhizomes of two *Acorus* species with mitogenic activity and inhibitory potential towards murine cancer cell lines, *Int. Immunopharmacol.* 5 (9) (2005) 1470–1478.
- [36] J.R. Nakkala, et al., Biological activities of green silver nanoparticles synthesized with *Acorus calamus* rhizome extract, *Eur. J. Med. Chem.* 85 (2014) 784–794.
- [37] S.R. Roy, P.C. Gadad, Effect of β -asarone on diethylnitrosamine-induced hepatocellular carcinoma in rats, *Indian J. Health Sci. Biomed. Res.* 9 (1) (2016) 82–88.
- [38] J.M. Lu, et al., Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems, *J. Cell Mol. Med.* 14 (4) (2009) 840–860.
- [39] P. Morales-Ramirez, et al., Sister-chromatid exchange induction produced by *in vivo* and *in vitro* exposure to alpha-asarone, *Mutat. Res.* 279 (4) (1992) 269–273.
- [40] European-commission, Opinion of the Scientific Committee on Food on the Presence of β -asarone in Flavours and Other Food Ingredients with Flavouring Properties, Scientific Committee on Food, 2002, pp. 1–15. Available at: https://ec.europa.eu/food/sites/food/files/safety/docs/sci-com_scf_out111_en.pdf.
- [41] V. Rajkumar, et al., Evaluation of cytotoxic potential of *Acorus calamus* rhizome, *Ethnobotanical Leaflet* 13 (2009) 832–839. Available at: <https://opensiuc.lib.siu.edu/ebl/vol2009/iss7/2>.
- [42] S.B. Sreejaya, K.S. Santhy, Antineoplastic and antioxidant activities of *Acorus calamus* L on swiss albino mice bearing Dalton's ascites lymphoma, *Asian J. Pharmaceut. Clin. Res.* 8 (6) (2015) 97–100. Available at: <https://innovareacademi.in/journals/index.php/ajpcr/article/view/7723/3346>.
- [43] S.B. Sreejaya, K.S. Santhy, Evaluation of antitumor properties of rhizome of *Acorus calamus* using Dalton's ascites lymphoma bearing swiss albino mice, *Int. J. Pharm. Bio. Sci.* 5 (4) (2014) 119–125. Available at: <https://ijpbs.net/abstract.php?article=MZYwMQ==>.
- [44] S.B. Sreejaya, et al., Biochemical changes in the serum of experimental animals treated with *Acorus calamus* rhizome, *Stud. Ethno-Med.* 11 (3) (2017) 216–220.
- [45] A. Parki, et al., Seasonal variation in essential oil compositions and antioxidant properties of *Acorus calamus* L, *Access. Med. (Basel)* 4 (4) (2017) E81.
- [46] K. Subathraa, T.V. Poonguzhali, *In vitro* studies on antioxidant and free radical scavenging activities of aqueous extract of *Acorus calamus* L, *Int. J. Curr. Sci.* 1 (2012) 169–173. Available at: <http://www.currentsciencejournal.info/issue/spdf/Subatra-Poonguzhali.pdf>.
- [47] S. Asha Devi, et al., Antioxidant properties of alpha asarone, *Asian J. Biochem.* 9 (2) (2014) 107–113.
- [48] Y.X. Yang, et al., Beta-asarone, a major component of *Acorus tatarinowii* Schott, attenuates focal cerebral ischemia induced by middle cerebral artery occlusion in rats, *BMC Complement Altern. Med.* 13 (2013) 236.
- [49] Y. Chen, et al., β -Asarone prevents autophagy and synaptic loss by reducing ROCK expression in asenescence-accelerated prone 8 mice, *Brain Res.* 1552 (2014) 41–54.
- [50] M.M. Thakare, S.J. Surana, β -Asarone modulate adipokines and attenuates high fat diet-induced metabolic abnormalities in Wistar rats, *Pharmacol. Res.* 103 (2016) 227–235.
- [51] S. Manikandan, R.S. Devi, Antioxidant property of alpha-asarone against noise-stress-induced changes in different regions of rat brain, *Pharmacol. Res.* 52 (6) (2005) 467–474.
- [52] N. Pages, et al., Activities of α -asarone in various animal seizure models and in biochemical assays might be essentially accounted for by antioxidant properties, *Neurosci. Res.* 68 (4) (2010) 337–344.
- [53] D. Sandep, C.K. Nair, Radioprotection by α -asarone: prevention of genotoxicity and hematopoietic injury in mammalian organism, *Mutat. Res.* 722 (1) (2011) 62–68.
- [54] H. Kumar, et al., Cognitive enhancing effects of alpha asarone in amnesic mice by influencing cholinergic and antioxidant defense mechanisms, *Biosci. Biotechnol. Biochem.* 76 (8) (2012) 1518–1522.
- [55] M. Sundaramahalingam, et al., Role of *Acorus calamus* and alpha-asarone on hippocampal dependent memory in noise stress exposed rats, *Pakistan J. Biol. Sci.* 16 (16) (2013) 770–778.
- [56] Q.X. Chen, et al., Anticonvulsant activity of acute and chronic treatment with α -asarone from *Acorus gramineus* in seizure models, *Biol. Pharm. Bull.* 36 (1) (2013) 23–30.